Cogent Biosciences Shares Fall After Public Offering News

Dow Jones

2025/07/09

By Stephen Nakrosis

Shares of Cogent Biosciences were trading in the red in Tuesday's after-hours market, following news the biotechnology company commenced an underwritten public offering for $150 million of its common stock.

In the late-trading session, the stock was down 4.9%, at $9.30. Shares had fallen as low as $8.80 after the bell before recovering some lost ground. The stock finished the day's regular session with a 4.6% gain, closing at $9.78.

The company said proceeds from the offering will be used for development, regulatory and commercial preparation activities relating to its lead drug candidate, bezuclastinib, which is being developed to inhibit cell mutations found in certain cancer patients. Proceeds will also go toward developing other product candidates, including novel targeted therapies to help patients fighting serious, genetically driven diseases, the company said.

All shares in the public offering are being provided by Cogent.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

July 08, 2025 17:03 ET (21:03 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2550573016"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550573016\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550573016?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-09 05:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550573016","market":"nz","top_or_hot":-1,"title":"Cogent Biosciences Shares Fall After Public Offering News","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/COGT\">Cogent Biosciences</a> were trading in the red in Tuesday's after-hours market, following news the biotechnology company commenced an underwritten public offering for $150 million of its common stock. \n</p>\n<p>\n  In the late-trading session, the stock was down 4.9%, at $9.30. Shares had fallen as low as $8.80 after the bell before recovering some lost ground. The stock finished the day's regular session with a 4.6% gain, closing at $9.78. \n</p>\n<p>\n  The company said proceeds from the offering will be used for development, regulatory and commercial preparation activities relating to its lead drug candidate, bezuclastinib, which is being developed to inhibit cell mutations found in certain cancer patients. Proceeds will also go toward developing other  product candidates, including novel targeted therapies to help patients fighting serious, genetically driven diseases, the company said. \n</p>\n<p>\n  All shares in the public offering are being provided by <a href=\"https://laohu8.com/S/CCOI\">Cogent</a>. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2025 17:03 ET (21:03 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cogent Biosciences Shares Fall After Public Offering News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCogent Biosciences Shares Fall After Public Offering News\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-07-09 05:03</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/COGT\">Cogent Biosciences</a> were trading in the red in Tuesday's after-hours market, following news the biotechnology company commenced an underwritten public offering for $150 million of its common stock. \n</p>\n<p>\n  In the late-trading session, the stock was down 4.9%, at $9.30. Shares had fallen as low as $8.80 after the bell before recovering some lost ground. The stock finished the day's regular session with a 4.6% gain, closing at $9.78. \n</p>\n<p>\n  The company said proceeds from the offering will be used for development, regulatory and commercial preparation activities relating to its lead drug candidate, bezuclastinib, which is being developed to inhibit cell mutations found in certain cancer patients. Proceeds will also go toward developing other  product candidates, including novel targeted therapies to help patients fighting serious, genetically driven diseases, the company said. \n</p>\n<p>\n  All shares in the public offering are being provided by <a href=\"https://laohu8.com/S/CCOI\">Cogent</a>. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2025 17:03 ET (21:03 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4089","symbol_name":"非傳統電信運營商","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550573016","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550573016","pubTimestamp":1752008580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Cogent Biosciences were trading in the red in Tuesday's after-hours market, following news the biotechnology company commenced an underwritten public offering for $150 million of its common stock.In the late-trading session, the stock was down 4.9%, at $9.30. Shares had fallen as low as $8.80 after the bell before recovering some lost ground. The stock finished the day's regular session with a 4.6% gain, closing at $9.78.The company said proceeds from the offering will be used for development, regulatory and commercial preparation activities relating to its lead drug candidate, bezuclastinib, which is being developed to inhibit cell mutations found in certain cancer patients. Proceeds will also go toward developing other  product candidates, including novel targeted therapies to help patients fighting serious, genetically driven diseases, the company said.All shares in the public offering are being provided by Cogent.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4089":"非传统电信运营商","COGT":"Cogent Biosciences, Inc.","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","BK4505":"高瓴资本持仓","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","CCOI":"Cogent Communications Group"},"translate_title":"公开发行消息传出后，Cogent Biosciences股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CCOI":1,"COGT":0.9},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Shares of Cogent Biosciences were trading in the red in Tuesday's after-hours market, following news the biotechnology company commenced an underwritten public offering for $150 million of its common stock. \n\n\n  In the late-trading session, the stock was down 4.9%, at $9.30. Shares had fallen as low as $8.80 after the bell before recovering some lost ground. The stock finished the day's regular session with a 4.6% gain, closing at $9.78. \n\n\n  The company said proceeds from the offering will be used for development, regulatory and commercial preparation activities relating to its lead drug candidate, bezuclastinib, which is being developed to inhibit cell mutations found in certain cancer patients. Proceeds will also go toward developing other  product candidates, including novel targeted therapies to help patients fighting serious, genetically driven diseases, the company said. \n\n\n  All shares in the public offering are being provided by Cogent. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 08, 2025 17:03 ET (21:03 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}